US5262178A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic use of enkephalinase
Assignee: Genentech Inc
•
Filing: 1991-03-11
•
Granted: 1993-11-16
•
Expires: 2011-03-11
Abstract
Abstract A method and therapeutic composition for the treatment of pathological disorders associated with endogenous peptides by the administration of enkephalinase or derivatives thereof.
Inventors
- 👤 Bernard Malfroy Camine
- 👤 Daniel B. Borson
- 👤 Jay A. Nadel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 20:58
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6489; C12N9/6494; C12Y; C12Y304/00; C12Y304/24; C12Y304/24011
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
31 words
A method of treatment of disorders associated with substance P susceptible to cleavage by enkephalinase comprising administration of a therapeutically effective dose of enkephalinase to an animal affected by such disorder.
Claim 2
Independent Claim
31 words
A method of treatment of disorders associated with substance P susceptible to cleavage by enkephalinase comprising administration of a therapeutically effective dose of enkephalinase to an animal affected by such disorder.
Claim 3
Dependent Claim
12 words
The method of treatment of claim 1 wherein the disorder is inflammation.
Claim 4
Dependent Claim
13 words
The method of treatment of claim 1 wherein the disorder is airway disease.
Claim 5
Dependent Claim
14 words
The method of treatment of claim 1 wherein the disorder is increased ophthalmic pressure.
Claim 6
Dependent Claim
13 words
The method of treatment of claim 3 wherein the airway disease is asthma.
Claim 7
Dependent Claim
13 words
The method of treatment of claim 1 wherein the disorder is a cough.
Claim 8
Dependent Claim
14 words
The method of claim 1 wherein the enkephalinase lacks the cytoplasmic and transmembrane domain.
Claim 9
Dependent Claim
12 words
The method of claim 1 wherein the enkephalinase lacks the transmembrane domain.
Claim 10
Dependent Claim
12 words
The method of claim 1 wherein the enkephalinase lacks the cytoplasmic domain.
Claim 11
Dependent Claim
14 words
The method of claim 1 wherein the enkephalinase is unaccompanied by associated native glycosylation.
Claim 12
Dependent Claim
11 words
The method of claim 1 wherein the enkephalinase is administered intramuscularly.
Claim 13
Dependent Claim
11 words
The method of claim 7 wherein the enkephalinase is administered intravenously.
Claim 14
Dependent Claim
13 words
The method of claim 9 wherein the enkephalinase is administered by intrapulmonary inhalation.
Claim 15
Dependent Claim
11 words
The method of claim 1 wherein the enkephalinase is administered topically.
Claim 16
Dependent Claim
24 words
The method of claim 1 wherein the enkephalinase is administered in a therapeutically effective dose of from about 0.01 mg/kg to about 25 mg/kg.
Claim 17
Dependent Claim
24 words
The method of claim 1 wherein the enkephalinase is administered in a therapeutically effective dose of from about 0.1 mg/kg to about 20 mg/kg.
Claim 18
Dependent Claim
13 words
The method of treatment of claim 2 wherein the inflammation is allergic dermatitis.
Claim 19
Dependent Claim
14 words
The method of claim 1 wherein the condition is contraction of iris sphincter muscles.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-11-15 | 1997-05-17 | 1997-11-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-11-15 | 2001-05-17 | 2001-11-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-11-15 | 2005-05-17 | 2005-11-16 | $7700.00 | Window Closed / Lapsed |